National Oesophago-Gastric Cancer Audit

Royal Berkshire NHS Foundation Trust

Thames Valley, Cancer Alliance

Management of High Grade Dysplasia patients

Time period: 2018-22

	Cancer Alliance		National
Number of High Grade Dysplasia patients in audit	51		1120
	Cancer Alliance		National
Method of Diagnosis			
– First diagnosis confirmed by second pathologist	N/A	93.3%	90.0%
Treatment planning			
– HGD plan discussed at MDT	N/A	100.0%	93.0%
– Treatment plan for active treatment	N/A	88.0%	82.0%
First treatment			
– Endoscopic therapy (such as endoscopic resection)	N/A	86.0%	78.0%
– Surveillance	N/A	6.0%	11.0%

NOTE: Percentages have been calculated based on the number of patients with recorded data for each variable and not the total number of patients in the Cancer Alliance.

Management of oesophago-gastric cancer patients

Time period: 2020-2022

	Organisation		National
Number of oesophago-gastric (OG) cancer patients in audit	57		19,865
Case ascertainment for OG cancer (%)	<65%		
Method of Diagnosis			
– Patients diagnosed after an emergency admission** ** Percent figure accounts for differences in mix of patients across organisations	<10	12.1%	13.1%
– Patients with referral source reported as unknown	0	0.0%	1.4%
Pre-treatment staging of cancer			
– Patients having staging CT scan recorded	57	100.0%	94.0%
Treatment planning			
– Patients having a plan for curative treatment	47	82.5%	37.2%
– Patients having a plan for non-curative treatment	10	17.5%	62.8%
– Patients with non-curative plans having chemotherapy or radiotherapy	N/A		34.7%